A Phase II, Open-label, Study in Subjects with BRAF V600EMutated Rare Cancers with Several Histologies to Investigate the Clinical Efficacy and Safety of the Combiantion Therapy of Dabrafenib and Trametinib

Cancer type: Solide tumores

Phase: II

Principal Investigator: Yachnin Jeffrey

Country: SE

Keywords: Sweden

Status: Inclusion completed

Link to